Lead Sponsor

Radboud University Medical Center

Collaborators

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

•Histological or cytological documented mRCC with a clear cell component
•Good or intermediate prognosis, defined as none (good risk) or 1-2 intermediate risk) of the below mentioned risk factors:
•* Karnofsky performance \<80
•* Time from diagnosis detection of metastases \< 1 year
•* Haemoglobin \< lower limit of normal (LLN)
•* Corrected calcium \> upper limit of normal (ULN)
•* Neutrophils \> ULN
•* Platelets \> ULN
•A watchful waiting period for 2 months is considered an option according to treating medical oncologist
•No prior systemic treatment for RCC (also non-adjuvant)
•Time from diagnosis of metastases \< 3 months
•Able to provide written informed consent
•Age ≥ 18 years

•Untreated central nervous system metastases, or symptomatic intracerebral metastases.
•Pregnant or breast feeding women.
•Any serious and/or unstable pre-existing medical, psychiatric, or other condition that would make the subject inappropriate for study participation including any serious condition that could interfere with subject's safety, provision of informed consent, or compliance with study procedure.